TheraRadar
Data updated: May 26, 2026

CLOTIC (clotrimazole)

Infectious Disease Approved 2025-09-26

CLOTIC is indicated for the treatment of Tinea Pedis; Tinea Cruris; Tinea Corporis.

Source: FDA Label • CARWIN PHARM ASSOC
1
Indication
--
Phase 3 Trials
1
Priority Reviews
0
Years on Market

Details

Status
Prescription
First Approved
2025-09-26
Patent Cliff
2042

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
OTIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: CLOTRIMAZOLE

CLOTIC Approval History

2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2025 to 2025
Sep 2025 ORIGINAL Priority
New Form · Type 3 - New Dosage Form

What CLOTIC Treats

3 indications

CLOTIC is approved for 3 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Tinea Pedis
  • Tinea Cruris
  • Tinea Corporis
Source: FDA Label

CLOTIC Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CLOTIC

3 of 17

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CLOTRIMAZOLE
CLOTRIMAZOLE
3 shared
Hikma
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE
3 shared
GLENMARK SPECLT
EXELDERM
SULCONAZOLE NITRATE
3 shared
JOURNEY
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT03005353 CSE Ph 2, Ph 3 completed Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.
NCT03115073 ProF-001_Phase IIa Ph 2, Ph 3 completed ProF-001_Phase IIa
NCT02847286 IPM 036 Ph 1 completed To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)
NCT01993823 results posted G238OTIII/11IA01 Ph 3 completed Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
NCT02713139 Frauen ACH-CLP-03(05/12) Ph 3 withdrawn Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLOTIC FDA Label Details

Indications & Usage

FDA Label (PDF)

CLOTIC is indicated for the treatment of Tinea Pedis; Tinea Cruris; Tinea Corporis.

View full patent landscape →
1 OB patents · 1 families · 38 international docs across 28 countries

CLOTIC Patents & Exclusivity

Latest Patent: May 2042
Exclusivity: Sep 2033

Patents (1 active)

US12246006 Expires May 26, 2042

Exclusivity

NP Until Sep 2028
GAIN Until Sep 2033
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for CLOTIC

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2042
  • 1 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 17 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.